ARX788, a Site-specific anti-HER2 Antibody Drug Conjugate, Demonstrates Potent and Selective Activity in HER2 Low and T-DM1 Resistant Breast and Gastric Cancers
ARX788, a Site-specific anti-HER2 Antibody Drug Conjugate, Demonstrates Potent and Selective Activity in HER2 Low and T-DM1 Resistant Breast and Gastric Cancers
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started